Sage Journals: Discover world-class research

Abstract

Background

Reactivation of viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are common in critically ill patients and have been described in patients with severe COVID-19. However, it is unclear whether these reactivations are associated with increased mortality and whether targeted treatments are beneficial.

Methods

In a retrospective single-center cohort study, patients with severe COVID-19 treated on our intensive care unit (ICU) were screened for EBV and CMV reactivation as detected by polymerase chain reaction. If present, patient characteristics, temporal connections to severe acute respiratory syndrome coronavirus 2 diagnosis and corticosteroid use, the use of targeted treatments as well as the course of disease and outcome were analyzed. As control group, non-COVID-19 patients with sepsis, treated within the same time period on our ICU, served as control group to compare incidences of viral reactivation.

Results

In 19 (16%) of 117 patients with severe COVID-19 treated on our ICU EBV reactivations were identified, comparable 18 (14%) of 126 in the non-COVID-19 control group (P = .672). Similarly, in 11 (9%) of 117 patients CMV reactivations were identified, comparable to the 16 (13%) of 126 in the non-COVID-19 sepsis patients (P = .296). The majority of EBV (58%) and CMV reactivations (55%) were detected in patients under systemic corticosteroid treatment. 7 (37%) of 19 patients with EBV reactivation survived the ICU stay, 2 (29%) of 7 patients with rituximab treatment and 5 (42%) of 12 patients without treatment (P = .568). Five (50%) of 10 patients with CMV reactivation survived the ICU stay, 5 (83%) of 6 patients with ganciclovir treatment and 0 of 4 patients without treatment (P = .048). Follow-up analysis in these patients showed that the initiation of treatment lead to decrease in viral load.

Conclusion

Critically ill patients with COVID-19 are at a high risk for EBV and CMV reactivations. Whether these reactivations are a cause of hyperinflammation and require targeted treatment remains uncertain. However, in patients with clinical deterioration or signs of hyperinflammation targeted treatment might be beneficial and warrants further studying.

Keywords

intensive care unit COVID-19 EBV CMV SARS-CoV-2 ARDS hyperinflammation

Get full access to this article

View all access options for this article.

References

Libert

Bigaillon

Chargari

, et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. Biomed J. 2015;38(1):70–76. doi:10.4103/2319-4170.132905

Ong

DSY

Bonten

MJM

Spitoni

, et al. Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock. Clin Infect Dis. 2017;64(9):1204-1210. doi:10.1093/cid/cix120

Walton

Muenzer

Rasche

, et al. Reactivation of multiple viruses in patients with sepsis. PLoS One. 2014;9(6):1-13. doi:10.1371/journal.pone.0098819

Textoris

Mallet

. Immunosuppression and herpes viral reactivation in intensive care unit patients: one size does not fit all. Crit Care. 2017;21(1):1-2. doi:10.1186/s13054-017-1803-1

Chiche

Forel

J-M

Roch

, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients*. Crit Care Med. 2009;37(6):1850-1857. doi:10.1186/s13613-020-00793-2

García-Martínez

Moreno-Artero

Jahnke

. SARS-CoV-2 and EBV coinfection. Med Clín. 2020;155(7):319-320. doi:10.1016/j.medcle.2020.06.010

Simonnet

Engelmann

Moreau

A-S

, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51(3):296-299. doi:10.1016/j.idnow.2021.01.005

Paolucci

Cassaniti

Novazzi

, et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021;104:315-319. doi:10.1016/j.ijid.2020.12.051

Saade

Moratelli

Azoulay

Darmon

. Herpesvirus reactivation during severe COVID-19 and high rate of immune defect. Infect Dis Now. 2021;S2666-S9919(21):000468-1. doi:10.1016/j.idnow.2021.07.005

10.

Lehner

Klein

Zoller

Peer

Bellmann

Joannidis

. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit Care. 2020;24(1):657. doi:10.1186/s13054-020-03384-6

11.

Limaye

Boeckh

. CMV In critically ill patients: pathogen or bystander? Rev Med Virol. 2010;20(6):372-379. doi:10.1002/rmv.664

12.

Papazian

Jaber

Hraiech

, et al. Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation. Ann Intensive Care. 2021;11(1):33. doi:10.1186/s13613-020-00793-2

13.

Kanakry

Ambinder

. The biology and clinical utility of EBV monitoring in blood. Curr Top Microbiol Immunol. 2015;391:475-499. doi:10.1007/978-3-319-22834-1_17

14.

Group

TRC

. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

Reactivation of EBV and CMV in Severe COVID-19—Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients